Former Johnson & Johnson CEO Alex Gorsky joined in a $60 million series B financing round for Causaly, an artificial intelligence-powered biomedical research company.
Causaly plans to use the new funding to extend its product lead and expand its commercial relationships. The company's AI platform is used by 12 of the top 20 pharmaceutical companies, according to a July 13 news release.
The latest funding round brings Causaly's total raised to $93 million.
"Recent advances in AI open completely new possibilities, and there is a great need for transparent AI systems that science leaders can trust," Causaly CEO and co-founder Yiannis Kiachopoulos said in the release. "Knowledge is the lifeblood of research organizations, and we are committed to our mission to make it discoverable, working with our customers to make sense of their scientific data and apply insights to enable evidence-driven decisions.